Sequestration of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A, a receptor for maternal malaria: monoclonal antibodies against the native parasite ligand reveal pan-reactive epitopes in placental isolates.
Plasmodium falciparum parasites express variant adhesion molecules on the surface of infected erythrocytes (IEs), which act as targets for natural protection. Recently it was shown that IE sequestration in the placenta is mediated by binding to chondroitin sulfate A via the duffy binding-like (DBL)-gamma 3 domain of P falciparum erythrocyte membrane protein 1 (PfEMP1(CSA)). Conventional immunization procedures rarely result in the successful production of monoclonal antibodies (mAbs) against such conformational vaccine candidates. Here, we show that this difficulty can be overcome by rendering Balb/c mice B cells tolerant to the surface of human erythrocytes or Chinese hamster ovary (CHO) cells before injecting P falciparum IEs or transfected CHO cells expressing the chondroitin sulfate A (CSA)-binding domain (DBL-gamma 3) of the FCR3 var(CSA) gene. We fused spleen cells with P3U1 cells and obtained between 20% and 60% mAbs that specifically label the surface of mature infected erythrocytes of the CSA phenotype (mIE(CSA)) but not of other adhesive phenotypes. Surprisingly, 70.8% of the 43 mAbs analyzed in this work were IgM. All mAbs immunoprecipitated PfEMP1(CSA) from extracts of (125)I surface-labeled IE(CSA). Several mAbs bound efficiently to the surface of CSA-binding parasites from different geographic areas and to placental isolates from West Africa. The cross-reactive mAbs are directed against the DBL-gamma 3(CSA), demonstrating that this domain, which mediates CSA binding, is able to induce a pan-reactive immune response. This work is an important step toward the development of a DBL-gamma 3-based vaccine that could protect pregnant women from pathogenesis. )
Lekana Douki
Jean-Bernard
JB
Unité de Parasitologie Expérimentale, Faculté de Médecine, Université de la Méditerranée (Aix-Marseille II), Marseille, France.
Traore
Boubacar
B
Costa
Fabio T M
FT
Fusaï
Thierry
T
Pouvelle
Bruno
B
Sterkers
Yvon
Y
Scherf
Artur
A
Gysin
Jürg
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D000953:Antigens, Protozoan / Q000032:analysis* / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D001665:Binding Sites; D016466:CHO Cells / Q000276:immunology; D002163:Cameroon; D002809:Chondroitin Sulfates / Q000378:metabolism*; D006224:Cricetinae; D004375:Duffy Blood-Group System; D004910:Erythrocyte Membrane / Q000737:chemistry; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism* / Q000469:parasitology; D005260:Female; D015870:Gene Expression; D006801:Humans; D007108:Immune Tolerance; D016778:Malaria, Falciparum / Q000469:parasitology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010920:Placenta / Q000469:parasitology*; D010963:Plasmodium falciparum / Q000254:growth & development / Q000276:immunology; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000469:parasitology; D015800:Protozoan Proteins / Q000235:genetics; D014162:Transfection
D000911:Antibodies, Monoclonal; D000953:Antigens, Protozoan; D004375:Duffy Blood-Group System; D015800:Protozoan Proteins; C085731:erythrocyte membrane protein 1, Plasmodium falciparum; D002809:Chondroitin Sulfates